The Beatrice Hunter Cancer Research Institute logo
  • Dr. Marianne Stanford, PhD


Vice President, Research & Development IMV Inc.
Adjunct Assistant Professor, Microbiology and Immunology, Dalhousie


Member, Vaccine Discovery Group, CCfV

Research Interests:

immunotherapy, T cell biology, translational cancer research

Research at IMV Inc. focuses on using our platform technology, DPX, to focus the immune system to treat cancer. IMV is developing a pipeline of novel therapeutic and preventive approaches for cancer and other serious diseases. Our proprietary platform provides a solution for product candidates with the potential to produce more rapid, robust and sustained immune responses. Our lead product, DPX-Survivac is in clinical development, inducing T cell responses to the tumor target survivin. In addition to being a widely recognized tumor-associated antigen (TAA), survivin also plays an important role in the dysregulated cell apoptosis and metastasis that are the hallmarks of cancer. We also actively explore immunotherapy combinations, including those with checkpoint inhibitors. 

Involvement with BHCRI to date:

Dr. Stanford is a BHCRI Associate Member who presented at a BHCRI Cancer Research Workshop


(902) 492-1819 x1009




130 Eileen Stubbs Avenue, Suite 19, Dartmouth NS B3B 2C4


Brewer KD, Weir GM, Dude I, Davis C, Parsons C, Penwell A, Rajagopalan R, Sammatur L, Bowen CV, Stanford MM. Unique depot formed by an oil based vaccine facilitates active antigen uptake and provides effective tumour control. J Biomed Sci. 2018 Jan 27;25(1):7. doi: 10.1186/s12929-018-0413-9.

Tremblay ML, Davis C, Bowen CV, Stanley O, Parsons C, Weir G, Karkada M, Stanford MM, Brewer KD. Using MRI cell tracking to monitor immune cell recruitment in response to a peptide-based cancer vaccine. Magn Reson Med. 2017 Nov 29. doi: 10.1002/mrm.27018.

Weir GM,, Karkada M, Hoskin D, Stanford MM, MacDonald L, Mansour M, Liwski RS .Combination of poly I:C and Pam3CSK4 enhances activation of B cells in vitro and boosts antibody responses to protein vaccines in vivo. PLOS one 2017 12(6) e0180073.
Weir GM, Hrystenko O, Quinton T, Berinstein NL, Stanford MM, Mansour M. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. Journal for ImmunoTherapy of Cancer 18(4):68 2016

Brewer KD, DeBay DR, Dude I, Davis C, Lake K, Parsons C, Rajagopalan R, Weir G, Stanford MM, Mansour M, Bowen CV. Using lymph node swelling as a potential biomarker for successful vaccination. Oncotarget 2016 May 24. doi: 10.18632/oncotarget.9580. [Epub ahead of print].

DeBay DR, Brewer KD, LeBlanc SA, Weir GM, Stanford MM, Mansour M, Bowen CV. Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines. Molecular Therapy Methods Clinical Development. 2015 Dec 16;2:15048. doi: 10.1038/mtm.2015.48. eCollection 2015.

Berinstein NL, Karkada M, Oza AM, Odunsi K,Villella JA,Nemunaitis JJ, Morse MA, Pejovic T, Bentley J, Buyse M, Nigam R, Weir GM, MacDonald LD,  Quinton T, Rajagopalan R, Sharp K, Penwell A, Sammatur L, Burzykowski T, Stanford MM, Mansour M. Survivin targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. Oncoimmunology. 2015. 2015 May 7;4(8):e1026529. eCollection 2015 Aug

Site by: Spectacle Group